Champions Oncology Delivers Record Revenue in Fiscal 2026, Maintains Growth Investments
Key Highlights for Investors
- Record annual revenue of \$59.4 million in fiscal 2026, up 4% year-over-year
- Fourth consecutive quarter of positive Adjusted EBITDA
- EBITDA income of \$158,000 in Q4 and \$1.6 million for the full year
- Oncology services margin increased to 51% in Q4, up from 41% in the prior-year period
- Continued strategic investment in radiopharmaceuticals, data platform, and commercial expansion
- No debt and \$4.9 million in cash at fiscal year-end
- Ongoing cost discipline despite increased operating expenses related to growth initiatives
Detailed Financial Performance
Fourth Quarter Results
- Q4 revenue reached \$13.8 million, a 12% increase from \$12.4 million in the same quarter last year.
- Cost of oncology revenue decreased by 6% to \$6.8 million, reflecting improved cost discipline, lower outsourced research costs, and reduced compensation expenses.
- Oncology services margin surged to 51%, compared to 41% in Q4 2025, due to higher revenue and cost control.
- Operating loss narrowed to \$522,000 (including \$357,000 stock-based compensation and \$322,000 depreciation/amortization), compared to a \$2.0 million loss in the prior year.
- Adjusted EBITDA turned positive at \$158,000, versus a loss of \$1.2 million in Q4 last year.
- Research & development (R&D) expense grew slightly to \$2.1 million, while sales and marketing climbed to \$2.8 million (up from \$2.3 million), reflecting a push to expand commercial operations.
- General and administrative (G&A) expense rose to \$2.6 million, mainly due to increased compensation and IT investments.
- Net cash used in operations was \$2.2 million, primarily from working capital timing (higher accounts receivable and lower deferred revenue), not core business weakness.
- Minimal capital expenditures and lease payments; cash position at \$4.9 million and no debt.
Full Year Fiscal 2026 Results
- Total revenue for FY26 was \$59.4 million, up 4% from \$56.9 million in FY25, despite the absence of a \$4.5 million data licensing transaction from the prior year.
- Operating expenses increased by \$8.2 million to \$60.6 million, driven by:
- Outsourced radiopharmaceutical costs (+\$3.0 million), as the company transitioned activities in-house
- Ongoing investments in commercial organization and data platform
- Loss from operations was \$1.1 million (includes \$1.2 million stock-based compensation, \$1.4 million depreciation/amortization, and \$111,000 loss on equipment disposal), compared to \$4.6 million operating income in FY25.
- Adjusted EBITDA for the year was \$1.6 million, down from \$7.1 million in the prior year, reflecting the non-recurring nature of the previous year’s data license transaction and higher investments.
- Cost of oncology revenue rose to \$30.9 million from \$28.4 million, mainly due to outsourced lab work during radiopharmacology capability build-up.
- Oncology services margin was 48% (down from 50%), reflecting temporary outsourcing costs.
- R&D expense jumped 33% to \$9.1 million, sales and marketing increased 23% to \$9.3 million, and G&A rose 19% to \$11.2 million—all reflecting strategic investments for future growth.
- Net income (loss) for the year was \$(1.2) million, compared to \$4.7 million in FY25.
- Basic and diluted EPS were \$(0.08), versus \$0.34 (basic) and \$0.33 (diluted) in the prior year. Adjusted EPS was \$0.12, down from \$0.51 in FY25.
Strategic Priorities and Shareholder-Relevant Updates
- Champions Oncology continues to invest in its radiopharmaceutical platform, data analytics, and commercial organization, believing these will fuel the next phase of growth and expand its competitive moat.
- Management highlighted the transition of radiopharmaceutical activities in-house as a key operational milestone, expected to improve margins in the future.
- The company remains focused on cost discipline and prudent capital allocation, balancing investments with profitability.
- No debt and a solid cash position provide financial flexibility.
- The absence of a one-time, high-margin data license deal from the prior year weighed on year-over-year comparisons, but the core business showed resilience and organic growth.
- Deferred revenue decreased to \$8.8 million from \$15.4 million, mainly due to timing of customer contracts and collections—an important metric for shareholders to monitor as it impacts future revenue recognition.
Conference Call and Additional Information
Management will hold a conference call to discuss results. Full details and replay information are available on the company’s investor relations website.
For a full breakdown, see the forthcoming Form 10-K and financial tables.
Potential Share Price Movers
- Record revenue and positive EBITDA despite the absence of a prior year one-time transaction may be seen as validation of the company’s core operating strength.
- Continued investment in growth initiatives (radiopharmaceuticals, data platform) could signal confidence in a scalable, differentiated business model, likely to be viewed positively by long-term investors.
- Short-term operating losses and cash used in operations due to timing effects—not business weakness—may create volatility but seem manageable given the company’s liquidity and no-debt balance sheet.
- Investors should watch deferred revenue and margins for signs of future acceleration as internalization and commercial investments pay off.
Non-GAAP Metrics and Definitions
The company uses non-GAAP metrics such as Adjusted EBITDA, Adjusted EPS, and Oncology Services Margin to better reflect underlying performance. These exclude stock-based compensation, depreciation/amortization, and other non-recurring items. Full reconciliations are provided in the financial statements.
About Champions Oncology
Champions Oncology is a global leader in preclinical and clinical research services, providing end-to-end oncology R&D solutions and data platforms for biopharma customers. Its largest annotated bank of patient-derived models and advanced bioanalytical platforms position it at the forefront of oncology drug development.
Disclaimer
This article includes forward-looking statements and is not investment advice. Actual results may differ due to risks and uncertainties. Investors should consult official filings and their financial advisor before making investment decisions.
